$25.89 Million in Sales Expected for Nektar Therapeutics (NASDAQ:NKTR) This Quarter

Equities research analysts predict that Nektar Therapeutics (NASDAQ:NKTR) will post sales of $25.89 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Nektar Therapeutics’ earnings, with estimates ranging from $24.50 million to $27.40 million. Nektar Therapeutics posted sales of $1.09 billion in the same quarter last year, which would indicate a negative year-over-year growth rate of 97.6%. The business is expected to issue its next earnings results on Wednesday, August 14th.

On average, analysts expect that Nektar Therapeutics will report full year sales of $107.47 million for the current year, with estimates ranging from $104.21 million to $111.92 million. For the next fiscal year, analysts expect that the company will post sales of $194.75 million, with estimates ranging from $115.24 million to $310.91 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. The business had revenue of $28.22 million during the quarter, compared to analysts’ expectations of $25.45 million. During the same period in the previous year, the business earned ($0.60) earnings per share.

Several research firms recently commented on NKTR. Zacks Investment Research cut Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. BidaskClub cut Zebra Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. William Blair restated a “buy” rating on shares of Nektar Therapeutics in a research report on Friday, June 14th. Cowen set a $200.00 target price on Lululemon Athletica and gave the stock a “buy” rating in a research report on Thursday, June 13th. Finally, ValuEngine cut Intersect ENT from a “buy” rating to a “hold” rating in a research report on Monday, June 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $68.50.

Nektar Therapeutics stock traded down $0.10 during midday trading on Friday, hitting $31.97. 1,017,889 shares of the company’s stock were exchanged, compared to its average volume of 1,372,475. Nektar Therapeutics has a 52-week low of $29.22 and a 52-week high of $69.76. The stock’s 50-day moving average price is $33.99. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94. The firm has a market capitalization of $5.57 billion, a P/E ratio of 8.46 and a beta of 2.74.

In other news, SVP Stephen K. Doberstein sold 3,461 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $31.37, for a total value of $108,571.57. Following the completion of the transaction, the senior vice president now directly owns 95,913 shares in the company, valued at approximately $3,008,790.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lutz Lingnau sold 10,000 shares of the company’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $34.63, for a total value of $346,300.00. Following the completion of the transaction, the director now owns 33,200 shares of the company’s stock, valued at $1,149,716. The disclosure for this sale can be found here. Insiders sold a total of 219,949 shares of company stock valued at $7,285,900 over the last quarter. Company insiders own 4.02% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. boosted its holdings in Nektar Therapeutics by 150.2% during the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 479 shares during the period. Quantamental Technologies LLC purchased a new stake in Nektar Therapeutics during the 1st quarter valued at about $27,000. CSat Investment Advisory L.P. boosted its holdings in Nektar Therapeutics by 279.2% during the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 790 shares during the period. Gemmer Asset Management LLC boosted its holdings in Nektar Therapeutics by 476.8% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,390 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 1,149 shares during the period. Finally, Enterprise Financial Services Corp purchased a new stake in Nektar Therapeutics during the 1st quarter valued at about $67,000. Hedge funds and other institutional investors own 92.15% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Recommended Story: Why do company’s buyback their stock?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.